Skip to search boxSkip to navigationSkip to main content

Mutational inactivation of STAG2 causes aneuploidy in human cancer

*Corresponding author for this work
  • Georgetown University School of Medicine
    ,
  • UT-Southwestern Medical Center
    ,
  • National Human Genome Research Institute (NHGRI)
    ,
  • National Cancer Institute (NCI)
    ,
  • Memorial Sloan-Kettering Cancer Center
    ,
  • University of California at San Francisco
Research Output:
Contribution to journal
Article
Peer-review

Publication metrics

PlumX, opens in new tab

Captures
325
Social media
15
Mentions
1
Citations
356

Abstract

Most cancer cells are characterized by aneuploidy, an abnormal number of chromosomes. We have identified a clue to the mechanistic origins of aneuploidy through integrative genomic analyses of human tumors. A diverse range of tumor types were found to harbor deletions or inactivating mutations of STAG2, a gene encoding a subunit of the cohesin complex, which regulates the separation of sister chromatids during cell division. Because STAG2 is on the X chromosome, its inactivation requires only a single mutational event. Studying a near-diploid human cell line with a stable karyotype, we found that targeted inactivation of STAG2 led to chromatid cohesion defects and aneuploidy, whereas in two aneuploid human glioblastoma cell lines, targeted correction of the endogenous mutant alleles of STAG2 led to enhanced chromosomal stability. Thus, genetic disruption of cohesin is a cause of aneuploidy in human cancer.

Bibliographic Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 1039-1043 (5 pages)

Journal (Volume, Issue Number)

Science (Volume 333, Issue 6045)

Publication milestones

  • Published - 19/08/2011

Publication status

Published - 19/08/2011

ISSN

0036-8075

Publication IDs

  • Scopus: 80051874823
  • PubMed: 21852505